Immunocore Holdings (IMCR) Cash & Equivalents (2019 - 2026)

Immunocore Holdings has reported Cash & Equivalents for 8 years, with the latest figure at $452.7 million in Q1 2026.

• Quarterly Cash & Equivalents fell 5.07% year-over-year to $452.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $452.7 million (down 5.07% YoY) and the FY2025 annual result came in at $467.7 million, up 2.63% from the prior year.
• Cash & Equivalents fell to $452.7 million in Q1 2026 per IMCR's latest filing, from $467.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $832.8 million in Q1 2024 and troughed at $262.0 million in Q2 2022.
• A 5-year average of $474.8 million and a median of $461.7 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents surged 63.5% in 2023, then tumbled 42.74% in 2025.
• Over 5 years, Cash & Equivalents stood at $390.0 million in 2022, then gained by 13.48% to $442.6 million in 2023, then grew by 2.96% to $455.7 million in 2024, then advanced by 2.63% to $467.7 million in 2025, then declined by 3.21% to $452.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $452.7 million, $467.7 million, and $498.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.